News & Views
Malaria vaccine trial results are positive
Oct 19 2011
In a study published in the New England Journal of Medicine (NEJM), the malaria vaccine candidate being trialled by scientists to provide young African children with significant protection against clinical and severe malaria was found to have an acceptable safety and tolerability profile.
The trial, conducted at 11 sites in seven countries across sub-Saharan Africa, showed that three doses of RTS,S reduced the risk of children aged five to 17 months suffering from clinical malaria by 56 per cent and saw a 47 per cent reduction in severe malaria.
Scientists noted that 6,000 children were involved in the study, with the findings based on the 12 months after the vaccine was administered.
"These data bring us to the cusp of having the world's first malaria vaccine, which has the potential to significantly improve the outlook for children living in malaria endemic regions across Africa," said Andrew Witty, chief executive officer of GSK.
Digital Edition
International Labmate Buyers' Guide 2024/25
June 2024
Buyers' Guide featuring: Product Listings & Manufacturers Directory Chromatography Articles - Enhancing HPLC Field Service with fast-response, non-invasive flowmeters - Digital transformatio...
View all digital editions
Events
Jul 07 2024 Dublin, Ireland
Jul 20 2024 Denver, CO, USA
Jul 21 2024 Cape Town, South Africa
Jul 28 2024 San Diego, CA USA
Jul 30 2024 Jakarta, Indonesia